Activity‐Directed Synthesis of Inhibitors of the p53/hDM2 Protein–Protein Interaction
暂无分享,去创建一个
Adam Nelson | S. Warriner | A. Nelson | Andrew J. Wilson | F. Hóbor | Adam Green | Fruzsina Hobor | Christopher Tinworth | Stuart Warriner | Andrew Wilson | Christopher P Tinworth | Adam I. Green | Fruzsina Hóbor
[1] M. Pirrung,et al. PREPARATION AND SCREENING AGAINST ACETYLCHOLINESTERASE OF A NON-PEPTIDE INDEXED COMBINATORIAL LIBRARY , 1995 .
[2] Danna Zhou,et al. d. , 1840, Microbial pathogenesis.
[3] A. Levine,et al. Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain , 1996, Science.
[4] Shanghai Yu,et al. SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression. , 2014, Cancer research.
[5] Gerhard Wagner,et al. A general framework for development and data analysis of competitive high-throughput screens for small-molecule inhibitors of protein-protein interactions by fluorescence polarization. , 2004, Biochemistry.
[6] A. Maguire,et al. Modern Organic Synthesis with α-Diazocarbonyl Compounds. , 2015, Chemical reviews.
[7] O. Koch,et al. Structure-Based Design of Inhibitors of Protein–Protein Interactions: Mimicking Peptide Binding Epitopes , 2015, Angewandte Chemie.
[8] T. Clackson,et al. A hot spot of binding energy in a hormone-receptor interface , 1995, Science.
[9] Thelma Thompson,et al. Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerization , 2012, Proceedings of the National Academy of Sciences.
[10] J. Murray,et al. Off-rate screening (ORS) by surface plasmon resonance. An efficient method to kinetically sample hit to lead chemical space from unpurified reaction products. , 2014, Journal of medicinal chemistry.
[11] Jason E Gestwicki,et al. Inhibitors of protein-protein interactions (PPIs): an analysis of scaffold choices and buried surface area. , 2018, Current opinion in chemical biology.
[12] J. Bajorath,et al. Recent Advances in Scaffold Hopping. , 2017, Journal of medicinal chemistry.
[13] A. ADoefaa,et al. ? ? ? ? f ? ? ? ? ? , 2003 .
[14] D. Scott,et al. Small molecules, big targets: drug discovery faces the protein–protein interaction challenge , 2016, Nature Reviews Drug Discovery.
[15] K. Zak,et al. A Unique Mdm2-Binding Mode of the 3-Pyrrolin-2-one- and 2-Furanone-Based Antagonists of the p53-Mdm2 Interaction. , 2016, ACS chemical biology.
[16] S. Warriner,et al. 2-O-alkylated para-benzamide α-helix mimetics: the role of scaffold curvature. , 2012, Organic & biomolecular chemistry.
[17] Dennis G. Gillingham,et al. Catalytic X-H insertion reactions based on carbenoids. , 2013, Chemical Society reviews.
[18] Adam Nelson,et al. Activity-Directed Synthesis with Intermolecular Reactions: Development of a Fragment into a Range of Androgen Receptor Agonists , 2015, Angewandte Chemie.
[19] Jeffrey P. Plante,et al. Oligobenzamide proteomimetic inhibitors of the p53–hDM2 protein–protein interaction† †Electronic supplementary information (ESI) available: Synthetic procedures, protein expression and FP assays. See DOI: 10.1039/b908207g Click here for additional data file. , 2009, Chemical communications.
[20] Binh Vu,et al. Deconstruction of a nutlin: dissecting the binding determinants of a potent protein-protein interaction inhibitor. , 2013, ACS medicinal chemistry letters.
[21] Xin Huang,et al. Rational design and binding mode duality of MDM2-p53 inhibitors. , 2013, Journal of medicinal chemistry.
[22] Oliver Zerbe,et al. Using a β‐Hairpin To Mimic an α‐Helix: Cyclic Peptidomimetic Inhibitors of the p53–HDM2 Protein–Protein Interaction , 2004 .
[23] Ajit Jadhav,et al. Fluorescence polarization assays in high-throughput screening and drug discovery: a review , 2016, Methods and applications in fluorescence.
[24] Peter Willett,et al. Maximum common subgraph isomorphism algorithms for the matching of chemical structures , 2002, J. Comput. Aided Mol. Des..
[25] L. Lam,et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets , 2013, Nature Medicine.
[26] P. Kollman,et al. Computational Alanine Scanning To Probe Protein−Protein Interactions: A Novel Approach To Evaluate Binding Free Energies , 1999 .
[27] O. Koch,et al. Strukturbasierte Entwicklung von Protein-Protein-Interaktionsinhibitoren: Stabilisierung und Nachahmung von Peptidliganden , 2015 .
[28] Pivotal Role of an Aliphatic Side Chain in the Development of an HDM2 Inhibitor. , 2014, ACS medicinal chemistry letters.
[29] Binh Vu,et al. Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical Development. , 2013, ACS medicinal chemistry letters.
[30] D. Bernard,et al. Small-Molecule Inhibitors of the MDM2–p53 Protein–Protein Interaction (MDM2 Inhibitors) in Clinical Trials for Cancer Treatment , 2014, Journal of medicinal chemistry.
[31] G. G. Stokes. "J." , 1890, The New Yale Book of Quotations.
[32] Dima Kozakov,et al. Relationship between Hot Spot Residues and Ligand Binding Hot Spots in Protein-Protein Interfaces , 2012, J. Chem. Inf. Model..
[33] Yi-Lin Huang,et al. Synthetic fermentation of bioactive non-ribosomal peptides without organisms, enzymes or reagents. , 2014, Nature chemistry.
[34] H. Davies,et al. Reactions of metallocarbenes derived from N-sulfonyl-1,2,3-triazoles. , 2014, Chemical Society reviews.
[35] Hyeong Jun An,et al. Estimating the size of the human interactome , 2008, Proceedings of the National Academy of Sciences.
[36] C. Ottmann,et al. Modulators of protein-protein interactions. , 2014, Chemical reviews.
[37] Alexander Dömling,et al. Robust generation of lead compounds for protein-protein interactions by computational and MCR chemistry: p53/Hdm2 antagonists. , 2010, Angewandte Chemie.
[38] A. Padwa,et al. Übergangsmetallkatalysierte Reaktionen von α-Diazocarbonylverbindungen – Einfluß der Liganden auf die Chemoselektivität† , 1994 .
[39] J. Canon,et al. Structure-based design of novel inhibitors of the MDM2-p53 interaction. , 2012, Journal of medicinal chemistry.
[40] J. Wells,et al. Small-molecule inhibitors of protein-protein interactions: progressing toward the reality. , 2014, Chemistry & biology.
[41] Michelle R. Arkin,et al. Small-molecule inhibitors of protein–protein interactions: progressing towards the dream , 2004, Nature Reviews Drug Discovery.
[42] Christine L. Andrews,et al. Nanoscale synthesis and affinity ranking , 2018, Nature.
[43] G. Maggiora,et al. Molecular similarity in medicinal chemistry. , 2014, Journal of medicinal chemistry.
[44] M. Williamson. Using chemical shift perturbation to characterise ligand binding. , 2013, Progress in nuclear magnetic resonance spectroscopy.
[45] L. Vassilev,et al. In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.
[46] M. Noble,et al. Understanding Small‐Molecule Binding to MDM2: Insights into Structural Effects of Isoindolinone Inhibitors from NMR Spectroscopy , 2011, Chemical biology & drug design.
[47] Nir London,et al. Druggable protein-protein interactions--from hot spots to hot segments. , 2013, Current opinion in chemical biology.
[48] D. Austin,et al. Ligand Effects on the Chemoselectivity of Transition Metal Catalyzed Reactions of α‐Diazo Carbonyl Compounds , 1994 .
[49] H. Davies,et al. Catalytic Asymmetric C−H Activation of Alkanes and Tetrahydrofuran , 2000 .
[50] D. Miller,et al. Synthetic applications of the O-H insertion reactions of carbenes and carbenoids derived from diazocarbonyl and related diazo compounds , 1995 .
[51] J. Canon,et al. Selective and potent morpholinone inhibitors of the MDM2-p53 protein-protein interaction. , 2014, Journal of medicinal chemistry.
[52] M. Doyle,et al. The influence of ligands on dirhodium(II) on reactivity and selectivity in metal carbene reactions , 2007 .
[53] Adam Nelson,et al. Efficient discovery of bioactive scaffolds by activity-directed synthesis , 2014, Nature Chemistry.
[54] P. Alam. ‘A’ , 2021, Composites Engineering: An A–Z Guide.
[55] P. Alam. ‘N’ , 2021, Composites Engineering: An A–Z Guide.
[56] Min Liu,et al. Systematic mutational analysis of peptide inhibition of the p53-MDM2/MDMX interactions. , 2010, Journal of molecular biology.
[57] Shanghai Yu,et al. Potent and orally active small-molecule inhibitors of the MDM2-p53 interaction. , 2009, Journal of medicinal chemistry.
[58] S. Warriner,et al. N-alkylated oligoamide alpha-helical proteomimetics. , 2010, Organic & biomolecular chemistry.